Back to Search
Start Over
The PILGRIM study: in silico modeling of a predictive low glucose management system and feasibility in youth with type 1 diabetes during exercise.
- Source :
-
Diabetes technology & therapeutics [Diabetes Technol Ther] 2014 Jun; Vol. 16 (6), pp. 338-47. Date of Electronic Publication: 2014 Jan 21. - Publication Year :
- 2014
-
Abstract
- Background: Predictive low glucose management (PLGM) may help prevent hypoglycemia by stopping insulin pump delivery based on predicted sensor glucose values.<br />Materials and Methods: Hypoglycemic challenges were simulated using the Food and Drug Administration-accepted glucose simulator with 100 virtual patients. PLGM was then tested with a system composed of a Paradigm(®) insulin pump (Medtronic, Northridge, CA), an Enlite™ glucose sensor (Medtronic), and a BlackBerry(®) (Waterloo, ON, Canada)-based controller. Subjects (n=22) on continuous subcutaneous insulin infusion (five females, 17 males; median [range] age, 15 [range, 14-20] years; median [range] diabetes duration, 7 [2-14] years; median [range] glycated hemoglobin, 8.0% [6.7-10.4%]) exercised until the PLGM system suspended insulin delivery or until the reference blood glucose value (HemoCue(®); HemoCue GmbH, Großostheim, Germany) reached the predictive suspension threshold setting.<br />Results: PLGM reduced hypoglycemia (<70 mg/dL) in silico by 26.7% compared with no insulin suspension, as opposed to a 5.3% reduction in hypoglycemia with use of low glucose suspend (LGS). The median duration of hypoglycemia (time spent <70 mg/dL) with PLGM was significantly less than with LGS (58 min vs. 101 min, respectively; P<0.001). In the clinical trial the hypoglycemic threshold during exercise was reached in 73% of the patients, and hypoglycemia was prevented in 80% of the successful experiments. The mean (±SD) sensor glucose at predictive suspension was 92±7 mg/dL, resulting in a postsuspension nadir (by HemoCue) of 77±22 mg/dL. The suspension lasted for 90±35 (range, 30-120) min, resulting in a sensor glucose level at insulin resumption of 97±19 mg/dL.<br />Conclusions: In silico modeling and early feasibility data demonstrate that PLGM may further reduce the severity of hypoglycemia beyond that already established for algorithms that use a threshold-based suspension.
- Subjects :
- Adolescent
Biosensing Techniques
Computer Simulation
Cross-Over Studies
Diabetes Mellitus, Type 1 drug therapy
Diabetes Mellitus, Type 1 physiopathology
Feasibility Studies
Female
Glycated Hemoglobin metabolism
Humans
Hypoglycemia prevention & control
Hypoglycemic Agents administration & dosage
Insulin administration & dosage
Male
Monitoring, Ambulatory
Young Adult
Blood Glucose metabolism
Diabetes Mellitus, Type 1 blood
Exercise
Hypoglycemia chemically induced
Hypoglycemic Agents adverse effects
Insulin adverse effects
Insulin Infusion Systems adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1557-8593
- Volume :
- 16
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Diabetes technology & therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 24447074
- Full Text :
- https://doi.org/10.1089/dia.2013.0327